Additionally, it is likely that the patients in the higher spending component have more severe or uncontrolled diabetes and have already failed first line oral treatment options, thus giving their treating physician multiple options in how to escalate their care, either by adding multiple oral drugs to their treatment plan, or moving on to injectable insulin. This evidence concerns the gene INS and diabetes mellitus.